SUNLO Trademark

Trademark Overview


On Tuesday, July 26, 2016, a trademark application was filed for SUNLO with the United States Patent and Trademark Office. The USPTO has given the SUNLO trademark a serial number of 87116827. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 27, 2020. This trademark is owned by Allergan Pharmaceuticals International Limited. The SUNLO trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
sunlo

General Information


Serial Number87116827
Word MarkSUNLO
Filing DateTuesday, July 26, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 27, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2016

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile ointments; ocular wetting solutions, artificial tears and formulations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Pseudo MarkSUN LO; SUN LOW

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 29, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Pharmaceuticals International Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDublin 17
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin 17
IE

Trademark Events


Event DateEvent Description
Monday, January 27, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 27, 2020ABANDONMENT - NO USE STATEMENT FILED
Thursday, March 21, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 20, 2019EXTENSION 5 GRANTED
Friday, March 15, 2019EXTENSION 5 FILED
Wednesday, March 20, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, March 15, 2019TEAS EXTENSION RECEIVED
Tuesday, November 6, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 2, 2018EXTENSION 4 GRANTED
Friday, November 2, 2018EXTENSION 4 FILED
Friday, November 2, 2018TEAS EXTENSION RECEIVED
Saturday, June 16, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 14, 2018EXTENSION 3 GRANTED
Thursday, June 14, 2018EXTENSION 3 FILED
Thursday, June 14, 2018TEAS EXTENSION RECEIVED
Friday, November 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 15, 2017EXTENSION 2 GRANTED
Wednesday, November 15, 2017EXTENSION 2 FILED
Wednesday, November 15, 2017TEAS EXTENSION RECEIVED
Tuesday, May 9, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 5, 2017EXTENSION 1 GRANTED
Friday, May 5, 2017EXTENSION 1 FILED
Friday, May 5, 2017TEAS EXTENSION RECEIVED
Tuesday, January 17, 2017ASSIGNED TO EXAMINER
Tuesday, December 27, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 1, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 1, 2016PUBLISHED FOR OPPOSITION
Wednesday, October 12, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 27, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, September 27, 2016ASSIGNED TO LIE
Tuesday, September 13, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 2, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, September 2, 2016LETTER OF SUSPENSION E-MAILED
Friday, September 2, 2016SUSPENSION LETTER WRITTEN
Thursday, September 1, 2016ASSIGNED TO EXAMINER
Saturday, July 30, 2016NOTICE OF PSEUDO MARK E-MAILED
Friday, July 29, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, July 29, 2016NEW APPLICATION ENTERED IN TRAM